To The Moon

$Intel(INTC)$announced a $15 billion common stock offering, with underwriters holding a 30-day option for an additional $2.25 billion in shares, bringing total potential proceeds to $17.25 billion. Funds will support growth initiatives including AI computing, Physical AI, custom chips, advanced packaging and foundry services, plus capital expenditures and working capital.

Shares fell ~4% on the news, a typical reaction. Stock offerings dilute existing shareholders, and with Intel in a heavy investment phase, markets naturally worry about future fundraising. However, paired with just-released Q2 results, the offering signals Intel may accelerate 14A and advanced packaging capacity buildout.

CEO Pat Gelsinger previously set two conditions for higher capex: proven process technology and sufficient demand visibility. Per recent roadshows, both have made meaningful progress. With equipment purchases, facility construction and prepayments due over ~18 months, the financing was moved forward.

A distinction must be drawn between disclosed facts and market speculation.

Intel only stated proceeds will fund capex, working capital and general corporate purposes, with no specific customer contracts announced. Market speculation links the offering to 14A flagship customers, but this remains unconfirmed. A more bullish read: Intel must lock in equipment and capacity first to secure long-term supply deals with large clients; waiting for contract announcements would delay expansion.

Fab capital requirements are substantial. Estimates put ~40,000 wafers/month capacity at ~$17 billion, enough to serve one Apple-sized customer. A greenfield 20,000 wafers/month 2nm-class fab could cost nearly $30 billion. The $15–17.25 billion offering supports a meaningful capacity ramp but falls short of fully funding Foundry’s long-term needs.

Intel’s fundamentals are improving. Q2 revenue topped $16 billion, up ~25% YoY and ~$1.65 billion above consensus — its 8th consecutive beat. Data Center revenue rose 59%, driven by AI inference, server CPUs and general compute demand. Q3 guidance of $15.8–16.8 billion has a midpoint well above the prior $15.16 billion consensus.

Earnings trends are equally notable. Q2 GAAP operating income hit ~$1.8 billion vs. a ~$3.2 billion loss a year prior; non-GAAP EPS of $0.42 beat consensus by ~$0.20. Gross margin recovered to 41.8%, lifted by 18A yields, pricing and factory efficiency. Panther Lake unit costs are reportedly down ~50% YTD, with ~20% further reduction expected by year-end.

Foundry remains the highest-risk segment. It posted a ~$2.1 billion Q2 operating loss, though narrowed by ~$350 million sequentially. Customer engagement on 14A has deepened following PDK progress, per management. External Foundry wins, EMIB packaging orders or clearer long-term contracts would validate the offering as expansion capital; prolonged order delays would reignite capital allocation concerns.

Intel has several new growth drivers. ASIC annualized revenue is near $2 billion, with management targeting ~$4 billion medium-term. As AI workloads shift to inference and multi-agent applications, demand for CPUs, custom chips and advanced packaging is rising, creating revenue opportunities across server CPUs, ASIC design, manufacturing and packaging.

The balance sheet explains the equity financing choice. At Q2-end, Intel held $29.7 billion in cash/short-term investments and $8.4 billion in equity investments, with over $50 billion in debt. It also needs over $14 billion to repurchase Apollo’s 49% stake in its Irish fabs. While Q2 operating cash flow rebounded to ~$7 billion, high future capex would pressure credit ratings if funded internally. The all-common offering preserves investment-grade status and headroom for future spending.

Dilution is estimated at ~3%, subject to the overallotment option. With shares up ~375% over the past year, the financing comes at a far lower cost than at lows. However, the stock is 31% off its 52-week high, reflecting lingering debate over valuation, dilution and execution.

Three metrics will determine the offering’s merit: 14A external flagship customer wins, sustained Foundry loss narrowing, and conversion of new capex into revenue and utilization. Consensus 2027 EPS is ~$2.05, implying a ~49x P/E — much of the recovery thesis is already priced in.

My view is neutral-to-slightly positive. Near-term dilution and FCF pressure are real, and Foundry breakeven may slip from late-2027 to 2028. Yet if orders and 14A progress materialize, this financing could mark a key de-risking point for Intel’s expansion. It is a time to track execution data, not to declare a turnaround based solely on the $15 billion raise.$GraniteShares 2X Long INTC Daily ETF(INTW)$$Corgi INTC 2x Daily ETF(INT)$